Teacher Retirement System of Texas Has $223,000 Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)

Teacher Retirement System of Texas raised its position in Arcus Biosciences, Inc. (NYSE:RCUS) by 19.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 14,952 shares of the company’s stock after purchasing an additional 2,410 shares during the period. Teacher Retirement System of Texas’ holdings in Arcus Biosciences were worth $223,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Intech Investment Management LLC increased its holdings in Arcus Biosciences by 63.9% in the fourth quarter. Intech Investment Management LLC now owns 26,155 shares of the company’s stock worth $389,000 after purchasing an additional 10,196 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Arcus Biosciences during the 4th quarter worth approximately $954,000. Amundi increased its stake in shares of Arcus Biosciences by 137.0% in the 4th quarter. Amundi now owns 27,030 shares of the company’s stock valued at $403,000 after acquiring an additional 15,624 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Arcus Biosciences during the 4th quarter valued at $531,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Arcus Biosciences by 2.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 579,623 shares of the company’s stock worth $8,631,000 after purchasing an additional 12,644 shares during the period. 92.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on RCUS. Morgan Stanley cut their price target on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. HC Wainwright upgraded Arcus Biosciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $18.00 to $24.00 in a report on Wednesday, February 26th. Finally, Bank of America decreased their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $30.25.

Insider Buying and Selling

In other Arcus Biosciences news, Director Yasunori Kaneko purchased 20,000 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was purchased at an average price of $10.06 per share, for a total transaction of $201,200.00. Following the transaction, the director now owns 28,400 shares in the company, valued at $285,704. The trade was a 238.10 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Terry J. Rosen purchased 19,800 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was bought at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the acquisition, the chief executive officer now directly owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. The trade was a 0.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by insiders.

Arcus Biosciences Trading Down 2.0 %

Shares of RCUS stock opened at $7.70 on Wednesday. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm has a market cap of $809.04 million, a P/E ratio of -2.44 and a beta of 1.36. The company has a 50 day moving average of $10.86 and a 200-day moving average of $14.18. Arcus Biosciences, Inc. has a 12-month low of $7.51 and a 12-month high of $18.98.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The company had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Sell-side analysts anticipate that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.